Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ metabolism
Carcinoma, Renal Cell
/ drug therapy
Endogenous Retroviruses
/ metabolism
Everolimus
/ administration & dosage
Female
Follow-Up Studies
Humans
Kidney Neoplasms
/ drug therapy
Lymphocytes, Tumor-Infiltrating
Male
Nivolumab
/ administration & dosage
Prognosis
Retrospective Studies
Survival Rate
T-Lymphocytes
/ immunology
Transcriptome
Viral Envelope Proteins
/ metabolism
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
06
08
2020
revised:
16
10
2020
accepted:
17
11
2020
pubmed:
22
11
2020
medline:
11
2
2022
entrez:
21
11
2020
Statut:
ppublish
Résumé
We sought to validate levels of CD8 Tumor tissues (nivo: In the nivo (but not evero) arm, patients with high-IF biomarker density (24/116, 20.7%) had higher ORR (45.8% vs. 19.6%, High levels of CD8
Identifiants
pubmed: 33219016
pii: 1078-0432.CCR-20-3084
doi: 10.1158/1078-0432.CCR-20-3084
pmc: PMC8443005
mid: NIHMS1649346
doi:
Substances chimiques
Biomarkers, Tumor
0
Viral Envelope Proteins
0
Nivolumab
31YO63LBSN
Everolimus
9HW64Q8G6G
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1371-1380Subventions
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211482
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Oncogene. 2011 Nov 24;30(47):4697-706
pubmed: 21602888
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184
pubmed: 30670497
J Clin Invest. 2008 Mar;118(3):1099-109
pubmed: 18292810
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Cancer Res. 2016 Apr 15;76(8):2177-85
pubmed: 26862115
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Front Immunol. 2019 Jul 25;10:1611
pubmed: 31402908
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Front Immunol. 2020 May 07;11:784
pubmed: 32457745
J Clin Invest. 2018 Nov 1;128(11):4804-4820
pubmed: 30137025
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135306
Nat Med. 2020 Jun;26(6):909-918
pubmed: 32472114
Nat Rev Cancer. 2019 Mar;19(3):151-161
pubmed: 30723290
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831